Medpace Holdings, Inc. (NASDAQ:MEDP) Shares Acquired by Raymond James & Associates

Raymond James & Associates grew its position in Medpace Holdings, Inc. (NASDAQ:MEDPFree Report) by 15.1% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 47,009 shares of the company’s stock after buying an additional 6,177 shares during the quarter. Raymond James & Associates owned 0.15% of Medpace worth $14,410,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors have also modified their holdings of MEDP. Wellington Management Group LLP grew its stake in shares of Medpace by 312.6% in the third quarter. Wellington Management Group LLP now owns 421,313 shares of the company’s stock valued at $102,013,000 after buying an additional 319,210 shares in the last quarter. Wasatch Advisors Inc. boosted its holdings in Medpace by 12.1% in the first quarter. Wasatch Advisors Inc. now owns 2,728,392 shares of the company’s stock valued at $446,338,000 after purchasing an additional 294,103 shares during the period. Invesco Ltd. boosted its holdings in Medpace by 67.6% in the third quarter. Invesco Ltd. now owns 611,900 shares of the company’s stock valued at $148,159,000 after purchasing an additional 246,775 shares during the period. Virginia Retirement Systems ET AL purchased a new position in Medpace in the second quarter valued at $54,927,000. Finally, Millennium Management LLC boosted its holdings in Medpace by 102.3% in the fourth quarter. Millennium Management LLC now owns 450,938 shares of the company’s stock valued at $95,784,000 after purchasing an additional 228,001 shares during the period. 77.98% of the stock is owned by institutional investors and hedge funds.

Medpace Stock Down 1.4 %

Shares of MEDP stock opened at $392.51 on Wednesday. The stock has a market capitalization of $12.07 billion, a PE ratio of 44.20, a price-to-earnings-growth ratio of 2.14 and a beta of 1.38. Medpace Holdings, Inc. has a 52-week low of $185.43 and a 52-week high of $419.42. The stock’s 50-day moving average price is $372.46 and its 200 day moving average price is $307.83.

Medpace (NASDAQ:MEDPGet Free Report) last issued its quarterly earnings results on Monday, February 12th. The company reported $2.46 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.22 by $0.24. The firm had revenue of $498.40 million for the quarter, compared to analysts’ expectations of $498.72 million. Medpace had a return on equity of 63.98% and a net margin of 15.00%. The firm’s revenue for the quarter was up 26.5% on a year-over-year basis. During the same quarter in the previous year, the firm posted $2.12 EPS. Analysts expect that Medpace Holdings, Inc. will post 10.53 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other Medpace news, CEO August J. Troendle sold 100,000 shares of the business’s stock in a transaction that occurred on Wednesday, March 6th. The stock was sold at an average price of $412.98, for a total transaction of $41,298,000.00. Following the transaction, the chief executive officer now owns 4,833,019 shares in the company, valued at approximately $1,995,940,186.62. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. In other Medpace news, CEO August J. Troendle sold 100,000 shares of the business’s stock in a transaction that occurred on Wednesday, March 6th. The stock was sold at an average price of $412.98, for a total transaction of $41,298,000.00. Following the transaction, the chief executive officer now owns 4,833,019 shares in the company, valued at approximately $1,995,940,186.62. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, major shareholder Medpace Investors, Llc sold 50,000 shares of the business’s stock in a transaction that occurred on Friday, February 16th. The stock was sold at an average price of $391.75, for a total value of $19,587,500.00. Following the transaction, the insider now owns 5,539,947 shares in the company, valued at approximately $2,170,274,237.25. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 189,340 shares of company stock worth $76,651,647. Company insiders own 25.70% of the company’s stock.

Wall Street Analyst Weigh In

Several analysts have recently weighed in on MEDP shares. Robert W. Baird boosted their target price on Medpace from $312.00 to $408.00 and gave the company an “outperform” rating in a report on Wednesday, February 14th. Deutsche Bank Aktiengesellschaft started coverage on Medpace in a report on Monday, March 18th. They issued a “hold” rating and a $395.00 target price for the company. UBS Group raised Medpace from a “neutral” rating to a “buy” rating and boosted their target price for the company from $282.00 to $452.00 in a report on Thursday, February 15th. Finally, StockNews.com downgraded Medpace from a “buy” rating to a “hold” rating in a report on Saturday, March 23rd. Two equities research analysts have rated the stock with a hold rating and three have assigned a buy rating to the company’s stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $382.00.

Check Out Our Latest Stock Report on Medpace

About Medpace

(Free Report)

Medpace Holdings, Inc provides clinical research-based drug and medical device development services in North America, Europe, and Asia. The company offers a suite of services supporting the clinical development process from Phase I to Phase IV in various therapeutic areas. It provides clinical development services to the pharmaceutical, biotechnology, and medical device industries; and development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support services.

Recommended Stories

Institutional Ownership by Quarter for Medpace (NASDAQ:MEDP)

Receive News & Ratings for Medpace Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medpace and related companies with MarketBeat.com's FREE daily email newsletter.